NCT03021941View on ClinicalTrials.gov

Pharmacokinetics, Pharmacodynamics And Safety Study Of Elelyso(tm) In Pediatric Subjects With Type 1 Gaucher Disease

PHASE4WithdrawnINTERVENTIONAL
0
Timeline

Start Date

July 31, 2019

Primary Completion Date

June 30, 2020

Study Completion Date

June 30, 2020

Conditions
Type 1 Gaucher Disease
Interventions
DRUG

Elelyso 60 units/kg

All patients receive Elelyso 60 units/kg.

Trial Locations (1)

22030

O&O Alpan LLC, Fairfax

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY